S. 864

119th CongressIn committee

HELP Copays Act

Sponsored by Roger Marshall (Republican-KS)

Healthcare Costs & Access Healthcare & Public Health Medicare & Medicaid

Cosponsors

Actions

Roll calls

Amendments

Related bills

Actions

Mar 19, 2026 · Senate

Committee on Health, Education, Labor, and Pensions. Hearings held.

Mar 5, 2025 · Library of Congress

Introduced in Senate

Mar 5, 2025 · Senate

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest activity

Activity

July 2026

Lobbying reported · Sanofi US Services · Jul 21

Sanofi US Services reported 2nd Quarter (Apr 1 - June 30) lobbying for Sanofi US Services — $920,000

BillsH.R. 1 H.R. 5376 H.R. 6423 H.R. 7174 H.R. 7834 H.R. 8698 H.R. 9102 S. 43 S. 832 S. 864 S. 1339 S. 1542 S. 3131 S. 4504

Lobbying reported · EMD Serono · Jul 21

EMD Serono reported 2nd Quarter (Apr 1 - June 30) lobbying for EMD Serono — $700,000

BillsH.R. 1 H.R. 220 H.R. 1492 H.R. 3838 H.R. 4317 H.R. 6703 H.R. 6797 H.R. 8800 S. 832 S. 864 S. 882 S. 891 S. 1071 S. 2296 S. 3345

Lobbying reported · Todd Strategy Group · Jul 21

Todd Strategy Group reported 2nd Quarter (Apr 1 - June 30) lobbying for Pharmaceutical Research and Manufacturers of America (PhRMA) — $80,000

BillsS. 864

Lobbying reported · Biotechnology Innovation Organization · Jul 21

Biotechnology Innovation Organization reported 2nd Quarter (Apr 1 - June 30) lobbying for Biotechnology Innovation Organization — $2,360,000

Lobbying reported · Todd Strategy Group · Jul 21

Todd Strategy Group reported 2nd Quarter (Apr 1 - June 30) lobbying for Merck & — $50,000

BillsS. 864

Lobbying reported · Todd Strategy Group · Jul 21

Todd Strategy Group reported 2nd Quarter (Apr 1 - June 30) lobbying for Johnson & Johnson Services — $100,000

BillsS. 864

Lobbying reported · Todd Strategy Group · Jul 21

Todd Strategy Group reported 2nd Quarter (Apr 1 - June 30) lobbying for EMD Serono — $50,000

BillsS. 864

Lobbying reported · Biogen · Jul 20

Biogen reported 2nd Quarter (Apr 1 - June 30) lobbying for Biogen — $1,060,000

BillsH.R. 1262 H.R. 1492 H.R. 3747 H.R. 4317 H.R. 6130 H.R. 6837 S. 832 S. 864 S. 3267 S. 3345

Lobbying reported · Venable · Jul 20

Venable reported 2nd Quarter (Apr 1 - June 30) lobbying for Patient Access Network Foundation — $40,000

BillsH.R. 3521 H.R. 6423 S. 864 S. 4440

Lobbying reported · American College of Rheumatology · Jul 20

American College of Rheumatology reported 2nd Quarter (Apr 1 - June 30) lobbying for American College of Rheumatology — $180,000

Lobbying reported · Todd Strategy Group · Jul 20

Todd Strategy Group reported 2nd Quarter (Apr 1 - June 30) lobbying for Astrazeneca Pharmaceuticals — $80,000

BillsS. 864

Lobbying reported · America's Health Insurance Plans (ahip) · Jul 20

America's Health Insurance Plans (ahip) reported 2nd Quarter (Apr 1 - June 30) lobbying for America's Health Insurance Plans (ahip) — $3,010,000

BillsH.R. 1 H.R. 247 H.R. 379 H.R. 584 H.R. 608 H.R. 610 H.R. 842 H.R. 935 H.R. 950 H.R. 957 H.R. 1096 H.R. 1117 H.R. 1157 H.R. 1162 H.R. 1397 H.R. 1403 H.R. 1523 H.R. 1614 H.R. 1627 H.R. 1775 H.R. 1776 H.R. 1805 H.R. 1867 H.R. 1899 H.R. 1924 H.R. 2013 H.R. 2045 H.R. 2049 H.R. 2079 H.R. 2199 H.R. 2309 H.R. 2433 H.R. 2450 H.R. 2528 H.R. 2533 H.R. 2553 H.R. 2554 H.R. 2571 H.R. 2586 H.R. 2610 H.R. 2636 H.R. 2741 H.R. 3000 H.R. 3023 H.R. 3069 H.R. 3415 H.R. 3493 H.R. 3527 H.R. 3546 H.R. 3701 H.R. 3789 H.R. 3808 H.R. 4093 H.R. 4206 H.R. 4231 H.R. 4313 H.R. 4317 H.R. 4406 H.R. 4559 H.R. 4605 H.R. 4623 H.R. 4641 H.R. 4710 H.R. 5081 H.R. 5145 H.R. 5243 H.R. 5281 H.R. 5371 H.R. 5509 H.R. 5526 H.R. 5582 H.R. 5584 H.R. 6010 H.R. 6232 H.R. 6248 H.R. 6255 H.R. 6361 H.R. 6703 H.R. 6951 H.R. 6974 H.R. 7023 H.R. 7064 H.R. 7164 H.R. 7189 H.R. 7409 H.R. 7537 H.R. 7727 H.R. 7778 H.R. 7787 H.R. 7790 H.R. 7803 H.R. 7837 H.R. 7871 H.R. 8270 H.R. 8375 H.R. 8377 H.R. 8684 H.R. 8779 H.R. 8875 H.R. 9393 H.R. 9504 S. 339 S. 483 S. 526 S. 529 S. 652 S. 717 S. 729 S. 752 S. 864 S. 882 S. 891 S. 931 S. 939 S. 976 S. 1040 S. 1056 S. 1082 S. 1096 S. 1227 S. 1261 S. 1637 S. 1753 S. 1816 S. 1818 S. 1847 S. 1954 S. 1973 S. 2237 S. 2289 S. 2345 S. 2355 S. 2356 S. 2497 S. 2556 S. 2620 S. 2658 S. 2709 S. 2903 S. 3014 S. 3599 S. 3642 S. 3690 S. 3727 S. 3729 S. 3750 S. 3751 S. 3762 S. 3822 S. 3829 S. 3834 S. 3848 S. 3886 S. 3990 S. 4189 S. 4332 S. 4355 S. 4384 S. 4509 S. 4512

Lobbying reported · Cystic Fibrosis Foundation · Jul 20

Cystic Fibrosis Foundation reported 2nd Quarter (Apr 1 - June 30) lobbying for Cystic Fibrosis Foundation — $270,000

BillsH.R. 2902 H.R. 4317 H.R. 6423 H.R. 6837 H.R. 7352 H.R. 7879 H.R. 7895 S. 864 S. 1406 S. 3549 S. 4875

Lobbying reported · AbbVie · Jul 20

AbbVie reported 2nd Quarter (Apr 1 - June 30) lobbying for AbbVie — $1,160,000

BillsH.R. 1 H.R. 1328 H.R. 4299 H.R. 5376 H.R. 5509 S. 864 S. 1040 S. 2903

Lobbying reported · Johnson & Johnson Services · Jul 20

Johnson & Johnson Services reported 2nd Quarter (Apr 1 - June 30) lobbying for Johnson & Johnson Services — $1,440,000

Lobbying reported · Pharmaceutical Research and Manufacturers of America (PhRMA) · Jul 20

Pharmaceutical Research and Manufacturers of America (PhRMA) reported 2nd Quarter (Apr 1 - June 30) lobbying for Pharmaceutical Research and Manufacturers of America (PhRMA) — $7,360,000

Lobbying reported · Alliance for Patient Access · Jul 20

Alliance for Patient Access reported 2nd Quarter (Apr 1 - June 30) lobbying for Alliance for Patient Access — $20,000

BillsH.R. 3267 H.R. 4231 H.R. 4317 H.R. 6423 S. 864 S. 1973 S. 3267

Lobbying reported · Williams And Jensen · Jul 20

Williams And Jensen reported 2nd Quarter (Apr 1 - June 30) lobbying for Bristol Myers Squibb — $80,000

BillsH.R. 830 S. 864

Lobbying reported · Williams And Jensen · Jul 20

Williams And Jensen reported 2nd Quarter (Apr 1 - June 30) lobbying for Beone Medicines USA — $80,000

BillsH.R. 830 S. 864

Lobbying reported · Williams And Jensen · Jul 20

Williams And Jensen reported 2nd Quarter (Apr 1 - June 30) lobbying for AbbVie — $30,000

BillsH.R. 830 S. 864